Table 1 Patient characteristics

Metastatic breast cancer

 No. of patients enrolled—100

 Age, years

 Hormone receptor status

  Median, range 59 (66–81)

  ER-positive/PR-positive—45 (45%)

 ECOG performance status

  ER-positive/PR-negative—16 (16%)

  ER-negative/PR-positive—5 (5%)

  0—66 (66%)

  ER-negative/PR-negative—18 (18%)

  1—23 (23%)

  Unknown—16 (16%)

  2—6 (6%)

 No. of disease sites

  Unknown—5 (5%)

  1—51 (51%)

 Histology

  2—21 (21%)

  Ductal—75(75%)

  3—11 (11%)

  Lobular—10 (10%)

  ≥ 4—2 (2%)

  Other—9(9%)

  Unknown—15 (15%)

  Unknown—6 (6%)

 Visceral disease

 Menopausal status

  Yes—37 (37%)

  Premenopausal—26 (26%)

  No—50 (50%)

  Perimenopausal—12 (12%)

  Unknown—13 (13%)

  Postmenopausal—53 (53%)

 Triple negative (ER negPRnegHER2neg)

  Unknown—9 (9%)

  11 (11%)

 HER2 status

  HER2 negative—64 (64%)

  Her2 positive—18 (18%)

  Unknown—18 (18%)